Policy Indications: UK Graduate route to open to international students on 1 July 2021 | Leadership Instincts: VP appeals to students to connect their knowledge with social relevance | Leadership Instincts: Catherine Dulac receives Nomis Distinguished Scientist and Scholar Award | Leadership Instincts: Online school reviews reflect school demographics more than effectiveness | Leadership Instincts: Researchers virtually open and read sealed historic letters | Cover Story: At Vantage Point | Management lessons: Why Aluminium Cans are Great for Packaging of Beverages? | Parent Interventions: Motivation to Perform | Parent Interventions: Poor Quality Carbs Harmful for Heart | Parent Interventions: Beat Covid stress with Yoga | Education Information: Suggestions invited on Draft UGC Regulations, 2021 | Life Inspirations: Little Acts of Kindness | Parent Interventions: Travel Local, Play Safe! | Art & Literature: IIT Hyderabad to hold techno-cultural fest Elan & nVision 2021 | Teacher Insights: Minister releases Study Material of Indian Knowledge Tradition Courses |

May 07, 2020 Thursday 10:50:21 PM IST

Scientists to culture novel coronavirus in human lung epithelial cell

Centre for Cellular and Molecular Biology (CCMB), Hyderabad has tied up with a Bengaluru-based company, Eyestem Research Private Limited, to take up research activities on COVID-19. Through this research collaboration, an attempt will be made to grow novel coronavirus in human cell lines, which will enable in vitro testing of potential drugs and vaccines against the COVID-19. The research team will use Eyestem's human lung epithelial cell culture system provided as part of its Anti-COVID Screening (ACS) platform to understand the molecular and pathological characteristics of the novel coronavirus, with a view of establishing a rational basis for testing potential drugs in vitro, said CCMB scientists.

CCMB is a constituent laboratory of the Council of Scientific and Industrial Research (CSIR) known for its cutting-edge research work on cellular and molecular biology. Eyestem Research Private Limited is a cell therapy start-up incubated at the Centre for Cellular and Molecular Platforms (C-CAMP), Bengaluru. C-CAMP is an initiative of the Department of Biotechnology, Ministry of Science and Technology.

Dr. Jogin Desai, CEO, Eyestem, expressed hope that CCMB will be able to leverage its platform and advance COVID-19 research that will help the country. “The ACS platform has been developed by Dr. Rajarshi Pal and his team and is a testament to our depth and expertise in cell therapy and disease modeling,” he said.

Eyestemis working to democratize access to cell therapy as well as disease modeling platforms and bring their benefit to a large section of humanity, added Dr. Desai.